Research Papers:

Impact of histologic subtypes and treatment modality among patients with primary central nervous system lymphoma: a SEER database analysis

Dai Chihara _, Nathan H. Fowler, Yasuhiro Oki, Michelle A. Fanale, Loretta J. Nastoupil, Jason R. Westin, Luis E. Fayad, Sattva S. Neelapu and Chan Yoon Cheah

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2018; 9:28897-28902. https://doi.org/10.18632/oncotarget.25622

Metrics: PDF 1679 views  |   HTML 2325 views  |   ?  


Dai Chihara1, Nathan H. Fowler2, Yasuhiro Oki2, Michelle A. Fanale2, Loretta J. Nastoupil2, Jason R. Westin2, Luis E. Fayad2, Sattva S. Neelapu2 and Chan Yoon Cheah3,4,5

1Department of Internal Medicine, University of New Mexico, Albuquerque, NM, USA

2Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

3Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia

4Department of Haematology, Pathwest Laboratory Medicine WA, Nedlands, WA, Australia

5Medical School, University of Western Australia, Crawley, WA, Australia

Correspondence to:

Dai Chihara, email: [email protected]

Keywords: primary central nervous system lymphoma; SEER; marginal zone lymphoma; follicular lymphoma; survival

Received: February 13, 2018    Accepted: May 31, 2018    Published: June 22, 2018


Primary central nervous system lymphoma (PCNSL) is a rare and aggressive extranodal presentation of lymphoma; however, the data for outcomes of patients with subtypes other than diffuse large B-cell lymphoma (DLBCL) are limited. Therefore, we analyzed overall survival (OS) of adult patients diagnosed with PCNSL by histologic subtype between 1998 and 2014 using the Surveillance, Epidemiology and End Results. A total of 4375 patients were identified. The median age of the patients was 64 years (range: 18-96). DLBCL was the most common histology (N=3,091), followed by follicular lymphoma (FL, N=83), peripheral T-cell lymphoma (PTCL, N=64), marginal zone lymphoma (MZL, N=63), Burkitt lymphoma (BL, N=27), small lymphocytic lymphoma (SLL, N=22), Hodgkin lymphoma (HL, N=13) and others (N=1,012). The 5-year OS rates were 30% in DLBCL, 66% in FL, 33% in PTCL, 79% in MZL, 42% in BL, 38% in SLL and 45% in HL. Radiation alone showed similar OS compared to no treatment in DLBCL, BL and PTCL, while radiation alone was associated with similar OS to chemotherapy or chemo-radiation in FL and MZL. The outcomes of patients with PCNSL are unfavorable; with the exception of FL and MZL which can potentially show prolonged survival with surgical resection or radiation monotherapy.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25622